The Natural History of Mitochondrial Diseases
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Descriptive measures: The natural history of mitochondrial disease
研究概览
简要总结
The Natural History of Mitochondrial (MITO) Diseases (a longitudinal study observing the natural history of mitochondrial diseases)
The goal of this observational study (non-randomised retrospective and prospective) is to fully characterise primary MITO disease; that includes both sexes/genders, over 18 years of age and healthy volunteers]. The main question[s] it aims to answer is to:
• better characterise MITO phenotypes (organ involvement, severity, progression) and collect biospecimens to create a biobank that can be used for future biomarker discovery to improve early diagnosis, prognostication and management of mitochondrial disease.
The study will be a longitudinal, retrospective, prospective, observational study of participants (400) with confirmed MITO and relevant controls followed for up to 10 years. Data will be collected at regularly scheduled standard-of-care (SOC), 6 to 12 monthly appointments.
The 100 control participants will therefore be comprised of (i) unaffected asymptomatic family members of MITO participants with no genetic risk; (ii) participants with non-MITO movement disorders that are not classified as MITO by their clinical presentation and genetic tests (for example Parkinson's disease) and/or (iii) age-matched healthy controls recruited from the NeuRA database of volunteers.
Demographic data, medical history, biochemical, histological, genetic, social and other clinical SOC data will be collected. Additionally, seizure and migraine frequency in participants who experience these, will be collected and a quality-of-life questionnaire (SF-12v2), as part of the validated neurological assessment using the Newcastle Mitochondrial Disease Adult Scale (NMDAS).
详细描述
Primary Mitochondrial Disease (MITO) is a serious and debilitating condition, often multi-systemic and requiring life-long monitoring and treatment of symptoms to reduce the risk of life-threatening episodes, metabolic crises, or acute illness. Although rare, MITO is the most common group of inherited metabolic diseases and is associated with abnormalities of the mitochondrial respiratory chain, which carries out oxidative phosphorylation to produce ATP (Gorman et al. 2016).
In adults, MITO is often a progressive multisystem disorder, with frequent, long-term monitoring and symptom management required to reduce the risk of an acute illness, and/or other life-threatening episodes and metabolic crises
Given that mtDNA mutations are typically transmitted through the maternal line, paternally related family members are not at risk and will represent asymptomatic controls. In sporadic cases such as chronic progressive external ophthalmoplegia (CPEO) that are typically caused by sporadic mtDNA deletions, family members are not at risk of carrying the disorder, and thus can act as family member controls. Similarly, those family members of participants with a nuclear DNA mutation such as autosomal dominant mitochondrial disease (e.g., OPA1 gene), and who do not carry the affected gene are also suitable asymptomatic controls.
This study will establish the AMDC Clinical Registry at NeuRA. Patients with confirmed MITO (the presence of pathogenic nuclear or mitochondrial DNA variants/deletion) and control participants that can include: biological relatives of MITO participants with no clinical disease and no genetic risk; participants with a clinically confirmed non-MITO neurologic disorder or age and gender-matched healthy controls followed over at least 120 months (10) years.
Study data will include detailed medical and social history, summary of clinical presentation and clinical social history collected through diaries or on clinical review; neurological examination findings; results of investigations performed as standard of care, including laboratory findings through blood tests, imaging studies, cardiac investigations, gastrointestinal transit studies, neurophysiological studies, and analysis of archived muscle and/or skin biopsies.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A clinical and/or genetically confirmed diagnosis of MITO.
- •Individuals > 18 years of age, managed by a specialist neurologist, with confirmed MITO
- •Control participants will comprise asymptomatic relatives of confirmed MITO patients with no clinical or genetic evidence of MITO; clinically confirmed non-MITO movement disease controls (from other clinics at NeuRA) or age/gender-matched healthy participants.
排除标准
- •Those participants who do NOT match the inclusion criteria above
- •Not willing to participate in the AMDC Clinical Registry
- •Not willing to undergo genetic testing
- •Not willing to provide consent
研究组 & 干预措施
MITO participants/patients
400 MITO patients will be observed over 10 years and having a confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain, or patients meeting the clinical diagnostic criteria for MITO using consensus scoring systems such as the Walker Criteria, or the Nijmegen criteria
干预措施: Confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain (Diagnostic Test)
Patients with a clinically confirmed non-MITO neuromuscular disorder
The study will form a 10-year, longitudinal, non-randomised, retrospective, and prospective, observational study of patients with MITO using controls who may be:
- asymptomatic biological relatives of MITO participants/patients
- patients with a clinically confirmed non-MITO neuromuscular disorder, or
干预措施: Confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain (Diagnostic Test)
Age and gender-matched healthy controls.
Age/gender-matched healthy controls will be recruited from the NeuRA database of volunteers
干预措施: Confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain (Diagnostic Test)
结局指标
主要结局
Descriptive measures: The natural history of mitochondrial disease
时间窗: 10 years
The primary outcome measure is the creation of a clinical database and biospecimen repository (biobank) with medical, health and lifestyle data to characterise the natural history of mitochondrial disease for each MITO patient. Data will be stratified by disease genotype, phenotype, age of onset, sequence and timing of major symptom onset, severity and progression of organ involvement and symptom progression, to identify any associations between parameters.
次要结局
- The natural history of mitochondrial disease(10 years)
